Literature DB >> 18777001

Percutaneous septal ablation after unsuccessful surgical myectomy for patients with hypertrophic obstructive cardiomyopathy.

Lothar Faber1, Dirk Welge, Detlef Hering, Thomas Butz, Olaf Oldenburg, Hubert Seggewiss, Dieter Horstkotte.   

Abstract

OBJECTIVE: To evaluate the long-term outcome of percutaneous septal ablation (PTSMA) after a previous myectomy.
BACKGROUND: Myectomy usually results in symptomatic improvement and reduction of dynamic obstruction in hypertrophic obstructive cardiomyopathy patients (HOCM-pts.). However, a few pts. remain with severe symptoms and obstruction, and need additional interventions.
METHODS: We reviewed our database of 450 pts. who underwent PTSMA in our institution, and identified 11 (7 women, 4 men, mean age: 50 +/- 14 years) with residual or recurrent NYHA class symptoms > or =III and significant left ventricular outflow obstruction (LVOTO) despite a previous myectomy 4 +/- 5 years ago. In-hospital and follow-up data covering 6 +/- 4 years, focusing on mortality and morbidity, symptoms, exercise capacity, and echocardiographic measures were collected.
RESULTS: PTSMA was performed by injection of 3.6 +/- 2.9 ml of alcohol. There was no peri-procedural or late death in this cohort. CK peaked at 614 +/- 434 U/l. In addition to two pts. who already had a pacemaker implanted, two more (18%) who both had pre-existing left bundle branch block were pacemaker-dependent after PTSMA. During follow-up, 9 pts. (81%) reported significant and stable improvement. Two pts. (18%) developed progressive class III symptoms until their last follow-up, one of these together with persistent AF and a non-fatal stroke, the other received an ICD for primary prophylaxis and entered our pre-transplant program. Echo-Doppler showed sustained LVOTO elimination without global LV dilatation in all cases.
CONCLUSIONS: PTSMA is an effective non-surgical option for treating symptoms and residual or recurrent LVOTO after a previous surgical myectomy. The high rate of conduction disturbances in this post-surgical cohort translated into a higher rate of pacemaker dependency after PTSMA.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18777001     DOI: 10.1007/s00392-008-0707-0

Source DB:  PubMed          Journal:  Clin Res Cardiol        ISSN: 1861-0684            Impact factor:   5.460


  21 in total

Review 1.  American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines.

Authors:  Barry J Maron; William J McKenna; Gordon K Danielson; Lukas J Kappenberger; Horst J Kuhn; Christine E Seidman; Pravin M Shah; William H Spencer; Paolo Spirito; Folkert J Ten Cate; E Douglas Wigle
Journal:  J Am Coll Cardiol       Date:  2003-11-05       Impact factor: 24.094

2.  Long term follow-up of surgical treatment of hypertrophic obstructive cardiomyopathy (HOCM): the role of concomitant cardiac procedures.

Authors:  Kazutomo Minami; Dietmar Boethig; Hajo Woltersdorf; Dirk Seifert; Reiner Körfer
Journal:  Eur J Cardiothorac Surg       Date:  2002-08       Impact factor: 4.191

3.  Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: acute results and 3-month follow-up in 25 patients.

Authors:  H Seggewiss; U Gleichmann; L Faber; D Fassbender; H K Schmidt; S Strick
Journal:  J Am Coll Cardiol       Date:  1998-02       Impact factor: 24.094

4.  Catheter-based septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: follow-up results of the TASH-registry of the German Cardiac Society.

Authors:  L Faber; H Seggewiss; F H Gietzen; H Kuhn; P Boekstegers; L Neuhaus; L Seipel; D Horstkotte
Journal:  Z Kardiol       Date:  2005-08

5.  Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy: long term follow up of the first series of 25 patients.

Authors:  L Faber; A Meissner; P Ziemssen; H Seggewiss
Journal:  Heart       Date:  2000-03       Impact factor: 5.994

6.  Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy.

Authors:  Steve R Ommen; Barry J Maron; Iacopo Olivotto; Martin S Maron; Franco Cecchi; Sandro Betocchi; Bernard J Gersh; Michael J Ackerman; Robert B McCully; Joseph A Dearani; Hartzell V Schaff; Gordon K Danielson; A Jamil Tajik; Rick A Nishimura
Journal:  J Am Coll Cardiol       Date:  2005-08-02       Impact factor: 24.094

7.  Mechanisms for recurrent left ventricular outflow tract obstruction after septal myectomy for obstructive hypertrophic cardiomyopathy.

Authors:  Kenji Minakata; Joseph A Dearani; Hartzell V Schaff; Patrick W O'Leary; Steve R Ommen; Gordon K Danielson
Journal:  Ann Thorac Surg       Date:  2005-09       Impact factor: 4.330

8.  Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy.

Authors:  U Sigwart
Journal:  Lancet       Date:  1995-07-22       Impact factor: 79.321

9.  Outcome of surgical myectomy after unsuccessful alcohol septal ablation for the treatment of patients with hypertrophic obstructive cardiomyopathy.

Authors:  Sherif F Nagueh; John M Buergler; Miguel A Quinones; William H Spencer; Gerald M Lawrie
Journal:  J Am Coll Cardiol       Date:  2007-08-06       Impact factor: 24.094

10.  Long-term results of left ventricular myotomy and myectomy for obstructive hypertrophic cardiomyopathy.

Authors:  R C Robbins; E B Stinson
Journal:  J Thorac Cardiovasc Surg       Date:  1996-03       Impact factor: 5.209

View more
  1 in total

Review 1.  Percutaneous Septal Ablation in Hypertrophic Obstructive Cardiomyopathy: From Experiment to Standard of Care.

Authors:  Lothar Faber
Journal:  Adv Med       Date:  2014-05-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.